WALTHAM, Mass. — Vizgen Inc., a spatial multi-omics company, said it has closed a $48 million financing round to support product innovation, global expansion, and scaled manufacturing as demand for spatial biology tools continues to grow.
The financing was led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors. The company said proceeds from the round will be used to execute its innovation roadmap, expand its ability to serve researchers worldwide, and scale manufacturing operations.
“Vizgen pioneered single-cell spatial genomics in 2022 with its launch of the MERSCOPE platform, and the company remains an industry leader because of its sustained innovation and scientific rigor,” said Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners. “The launch of MERSCOPE Ultra and MERFISH 2.0 are examples of Vizgen continuing to set the standard for technical excellence in the rapidly growing spatial biology field.”
Christian Uhrich, Investment Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany, said the firm remains committed to Vizgen’s long-term growth. “The company is now well-positioned to accelerate growth, achieve profitability, and unlock the full potential of its commercial portfolio and R&D pipeline, enabling researchers worldwide to explore cellular functions and interactions with unprecedented clarity and resolution,” Uhrich said.
Vizgen said it has reached several operational and scientific milestones since late 2024 that strengthen its support for researchers in biology and drug discovery. These include the launch of MERFISH 2.0 chemistry, expansion of its InSituPlex and STARVUE proteomics offerings, publication of more than 100 high-impact peer-reviewed articles, and the establishment of new academic and industry collaborations.
Chief Executive Officer Rob Carson said the financing provides the company with momentum entering 2026. “After a remarkable 15 months of accomplishment, the entire Vizgen team is excited to start 2026 with the capital we need to scale our platform and deliver customer experience excellence to scientists worldwide,” Carson said. “With the successful resolution of our prior litigation and now this important financing behind us, we are on a march to profitability. We have a clear path forward and the resources to execute on our vision of making spatial multi-omics an essential tool, accessible to every research lab.”
